To assess the potential of pharmacological BCL2 inhibition in B-lineage ALL, BCR-ABL-positive and -negative ALL cell lines were treated with the BCL2 inhibitor ABT-737 for 24 h, prior to assessment of cell death. Here, ABL1 is linked to acute lymphoblastic leukemia.